These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25941710)

  • 21. Ten years of pharmacovigilance in Italy: the experience of Emilia-Romagna region in the monitoring of drug's safety profile.
    Motola D; Melis M; Lo Bianco S; Buccellato E; Biagi C; Vaccheri A
    Expert Opin Drug Saf; 2014 Jul; 13(7):867-73. PubMed ID: 24809453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with spontaneous reporting of adverse drug reactions in Japan.
    Yamada T; Watanabe Y; Kusama M; Sugiyama Y; Ono S
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):468-76. PubMed ID: 23172714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Off-label prescriptions: patient safety first.
    Lancet Oncol; 2011 Sep; 12(9):825. PubMed ID: 21875558
    [No Abstract]   [Full Text] [Related]  

  • 24. Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance Centre.
    Shalviri G; Yousefian S; Gholami K
    J Clin Pharm Ther; 2012 Aug; 37(4):448-51. PubMed ID: 22122488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Causality Assessment in Pharmacovigilance: Still a Challenge.
    Ralph Edwards I
    Drug Saf; 2017 May; 40(5):365-372. PubMed ID: 28247280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacovigilance in developing countries (part II): a path forward.
    Elshafie S; Roberti AM; Zaghloul I
    Int J Clin Pharm; 2018 Aug; 40(4):764-768. PubMed ID: 29322474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systems pharmacology augments drug safety surveillance.
    Lorberbaum T; Nasir M; Keiser MJ; Vilar S; Hripcsak G; Tatonetti NP
    Clin Pharmacol Ther; 2015 Feb; 97(2):151-8. PubMed ID: 25670520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
    Yang W; Xiang YY; Xie YM; Shen H
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Developing a terminology in the French language for clinical practice and research in drug safety].
    Roulet L; Ballereau F; Lapeyre-Mestre M; Joris-Frasseren M; Asseray N
    Therapie; 2015; 70(3):283-92. PubMed ID: 25534521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.
    Awada Z; Zgheib NK
    Pharmacogenomics; 2014 Apr; 15(6):845-56. PubMed ID: 24897290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacovigilance in children].
    Autret-Leca E; Marchand MS; Cissoko H; Beau-Salinas F; Jonville-Béra AP
    Arch Pediatr; 2012 Aug; 19(8):848-55. PubMed ID: 22748689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
    Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
    Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacovigilance and use of online health information.
    Masoni M; Guelfi MR; Conti A; Gensini GF
    Trends Pharmacol Sci; 2013 Jul; 34(7):357-8. PubMed ID: 23759353
    [No Abstract]   [Full Text] [Related]  

  • 34. Towards better patient care: drugs to avoid in 2014.
    Prescrire Int; 2014 Jun; 23(150):161-5. PubMed ID: 25121155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Research on early warning signals of adverse drug reactions to parenterally administered xiyanping based on spontaneous reporting system (SRS) data].
    Wang ZF; Xiang YY; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3008-12. PubMed ID: 24471321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Study of analysis 1 390 adverse drug reactions cases of parenterally administered dengzhan xixin based on China's spontaneous response system].
    Li YY; Xiang YY; Xie YM; Shen H
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2998-3002. PubMed ID: 24471319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacovigilance and post-black market surveillance.
    Langlitz N
    Soc Stud Sci; 2009 Jun; 39(3):395-420. PubMed ID: 19848184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.